Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer
Sumit K. Subudhi, Luis M. Vence, Hao Zhao, Jorge Blando, Shalini S. Yadav, Qing Xiong, Alexandre Reuben, Ana M. Aparicio, Paul G. Corn, Brian F. Chapin, Louis L. Pisters, Patricia Troncoso, Rebecca S. Tidwell, Peter F. Thall, Chang‐Jiun Wu, Jianhua Zhang, Christopher L. Logothetis, P. Andrew Futreal, James P. Allison, Padmanee Sharma
Abstract
= 10). Patients in the favorable cohort had high intratumoral CD8 T cell density and IFN-γ response gene signature and/or antigen-specific T cell responses. Two patients with a relatively low TMB had T cell responses against unique neoantigens. Moreover, six of nine patients in the favorable group are still alive at the time of analysis, with survival ranging from 33 to 54 months after treatment. All 10 patients in the unfavorable cohort have succumbed to their disease and had survival ranging from 0.6 to 10.3 months. Collectively, our data indicate that immunological correlates associated with effector T cell responses are observed in patients with metastatic prostate cancer who benefit from ICB.